LGND
Ligand Pharmaceuticals Incorporated
299.00$
+0.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.5% | +10.2% | +34.1% | +24.8% | -17.4% | +5.9% | +5.1% | +142.4% | -48.3% | -13.3% | +23.1% | – | |
| – | -52.3% | +565.1% | -238.5% | – | -77.3% | +70.9% | -40.0% | +753.8% | -204.7% | – | +54.9% | – | |
| – | -10.0% | -24.7% | +185.6% | -30.8% | +1.7% | +1.3% | +10.5% | +102.7% | -5.5% | -42.0% | +21.8% | – | |
| – | -0.8% | +8.8% | -10.3% | +6.0% | -22.0% | +1,031.9% | -86.9% | +220.1% | -83.3% | -38.8% | +582.9% | – | |
| – | +9.1% | -31.5% | +60.9% | +38.9% | +4.6% | -26.6% | +7.3% | +41.0% | -12.0% | -16.7% | +39.8% | – | |
| – | +13.3% | -43.2% | +348.9% | -52.4% | +37.1% | +54.6% | -52.7% | -1.6% | +83.7% | -50.8% | +60.7% | – | |
| – | -209.1% | – | -739.2% | – | -406.6% | – | – | +550.5% | -63.5% | -13.3% | -50.5% | – | |
| – | +13,000.0% | +7.6% | +799.3% | -41.6% | +19.2% | -1.8% | +33.0% | -21.1% | +96.2% | -2.1% | +0.1% | – | |
| – | – | +563.5% | -157.6% | – | – | – | – | +1,157.6% | -59.8% | -142.7% | – | – | |
| – | – | – | -149.4% | – | -1,073.8% | – | – | +274.3% | -49.7% | -191.0% | – | – | |
| – | – | +373.6% | -160.3% | – | – | – | – | +2,319.5% | -61.8% | -129.8% | – | – | |
| – | – | +367.9% | -145.2% | – | -974.3% | – | – | +614.1% | -55.5% | -121.5% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.